[Form 4] Rhythm Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) – Form 4 insider filing

Director Christophe Jean reported two equity awards dated 24 Jun 2025:

• Stock option: 7,037 shares of common stock, exercise price $63.66, expiration 23 Jun 2035. The option vests in full on the earlier of 24 Jun 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
• Restricted stock units (RSUs): 4,712 units, each convertible into one common share. Vesting schedule mirrors the option grant; the RSUs have no expiration date.

Both grants are coded "A" (acquired) and were made directly to the reporting person. Following the transactions, Jean beneficially owns 7,037 stock options and 4,712 RSUs; no common shares were reported in Table I and no sales occurred.

The filing represents routine non-cash director compensation and does not disclose any open-market purchase or sale of Rhythm Pharmaceuticals stock.

Insights

Securities Analyst

TL;DR Routine director equity grants; no cash transactions; neutral for valuation.

The Form 4 shows standard annual board compensation: ~7k options at a strike near the recent trading range and ~4.7k RSUs. No changes to ownership of outstanding shares or insider buying/selling signals are present. While the grants moderately align director incentives with shareholders, the scale is immaterial relative to RYTM’s ~56 million share count and has no immediate EPS or cash-flow effect. Overall, the disclosure is procedural and should not affect valuation models or risk assessments.

Corporate Governance Expert

TL;DR Standard equity compensation; governance-aligned, financially immaterial.

The vest-on-earlier-date structure ties board tenure to shareholder meeting cadence, an increasingly common best practice. Grant size and one-year vesting horizon suggest a focus on near-term oversight rather than long-term retention. No red flags on timing (filed two days post-grant) or Rule 10b5-1 certification boxes. Impact on governance risk profile: neutral to slightly positive due to alignment, but quantitatively negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JEAN CHRISTOPHE

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$63.66	06/24/2025		A		7,037		(1)	06/23/2035	Common Stock	7,037	$0	7,037	D
Restricted Stock Units	(2)	06/24/2025		A		4,712		(3)	(3)	Common Stock	4,712	$0	4,712	D

Explanation of Responses:

1. The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

3. The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Christophe Jean	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Christophe Jean acquire in the 24 Jun 2025 Form 4 for RYTM?

He received 7,037 stock options at $63.66 and 4,712 restricted stock units; no common shares were bought or sold.

What is the vesting schedule for the new RYTM option and RSU grants?

Both awards fully vest on the earlier of 24 Jun 2026 or the day before Rhythm’s 2026 annual meeting, subject to continued board service.

What is the exercise price and expiration date of the stock options granted to the director?

The options are exercisable at $63.66 per share and expire on 23 Jun 2035.

Did the Form 4 report any open-market purchases or sales of RYTM stock?

No. The filing only discloses equity grants; there were no purchases or dispositions of existing shares.

How many derivative securities does Christophe Jean hold after the reported transactions?

He beneficially owns 7,037 stock options and 4,712 RSUs following the grants.